Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neofen Combo is a fixed-dose combination of ibuprofen (200 mg) and paracetamol (500 mg) developed by Belupo and distributed by Farmavita. It is indicated for the short-term relief of mild to moderate pain, including headache, migraine, back pain, menstrual pain, toothache, muscular pain, sore throat, and fever. The combination utilizes the synergistic effects of two distinct mechanisms of action: ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes to reduce prostaglandin synthesis, and paracetamol, an analgesic and antipyretic that primarily acts on the central nervous system to inhibit prostaglandin synthesis and raise the pain threshold. This multimodal approach provides faster, stronger, and longer-lasting pain relief compared to either active ingredient alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neofen Combo.